Pharscin Pharma: Company drug production license change and passing GMP compliance inspection

Pharscin Pharma announced that it recently received the "Drug Manufacturing License" issued by the Chongqing Municipal Drug Administration and two "Drug GMP Compliance Inspection Notification Letters" for its products. The changes include that the raw materials for the small-scale synthesis production line in Workshop 3 of the Rongchang District Industrial Park passed the compliance inspection for drug production quality management standards, and the addition of contract manufacturing for injectable Esomeprazole Sodium. Additionally, the production line for freeze-dried powder injections in Workshop 502 for injectable Esomeprazole Sodium also passed the compliance inspection for drug production quality management standards. Injectable Esomeprazole Sodium is a low-risk alternative treatment for gastroesophageal reflux disease when oral therapy is not applicable. The raw material for Agomelatine is used in the company's production of Agomelatine tablets, with a market share of 790 million yuan in 2024